Ike Swetlitz

(Bloomberg) -- Rite Aid Corp. and Amazon Pharmacy confirmed that Eli Lilly & Co.'s new weight-loss drug Zepbound is in short supply, as patient, pharmacist and doctor complaints mount.

Rite Aid, Amazon Pharmacy, and others said that the obesity shot was in short supply.

Eli Lilly & Co. stated that some sufferers might have hassle getting its new weight reduction drug Zepbound as complaints of backorders and delays mount throughout the US. “Because of the unprecedented demand for these medicines, some sufferers might expertise issue when making an attempt to fill their prescription at their pharmacy,” a Lilly spokesperson stated.

Eli Lilly & Co. 's weight-loss drug Zepbound is in shortage in the US, after mounting complaints by patients, doctors and pharmacists who were having trouble finding the drug.

Johnson & Johnson 's first-quarter profit beat estimates as the health giant's drug sales came in higher than Wall Street analysts expected.

The fast rise of prescriptions for Adderall and other stimulants, along with rampant online treatment and advertising, suggest the start of another drug crisis like the opioid epidemic, a senior Drug Enforcement Administration official said Thursday.

Hi, it’s Ike in Boston. Have a cough? It might not need antibiotics. More on that later, but first ...

(Bloomberg) -- Bristol Myers Squibb Co.'s first-quarter revenue beat Wall Street's expectations as sales of the blockbuster cancer medicine Revlimid didn't fall as quickly as analysts expected.

(Bloomberg) -- Cardinal Health Inc. shares fell the most in more than two months after the drug distributor lost a big contract with UnitedHealth Group Inc.’s pharmacy benefits subsidiary.Most Read from BloombergTrump Has Only $6.8 Million for Legal Fees With Trial UnderwayTikTok to Remove Executive Tasked With Fending Off US ClaimsRay Dalio’s Famous Trade Is Sputtering and Investors Are BailingUS Dollar’s Extended Reign Delivers Stark Wake-Up Call for MarketsS&P 500 Tops 5,000 as Earnings Kick

By Ike Swetlitz The fast rise of prescriptions for Adderall and other stimulants, along with rampant online treatment and advertising, suggest